Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Axogen Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Sep 14

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Aug 20

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Jul 29

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Jun 12

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Apr 16

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26

CEO

Axogen CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nir Naor	Chief Financial Officer	less than a year	US$509.68k	Veri yok
Karen Zaderej	Advisor	less than a year	US$5.53m	2.61% $ 16.4m
Erick DeVinney	Chief Innovation Officer	less than a year	US$1.51m	0.30% $ 1.9m
Todd Puckett	Vice President of Operations	less than a year	Veri yok	Veri yok
Harold Tamayo	Vice President of Finance & Investor Relations	no data	Veri yok	Veri yok
Marc Began	Executive VP	1.6yrs	Veri yok	Veri yok
Doris Quackenbush	Vice President of Sales	2.8yrs	Veri yok	Veri yok
Jens Kemp	Chief Marketing Officer	1.7yrs	Veri yok	Veri yok
Ivica Ducic	Chief Medical Officer	less than a year	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim: AXGN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Paul Thomas	Independent Director	4.1yrs	US$220.00k	0.049% $ 306.2k
Guido Neels	Independent Director	9.2yrs	US$217.50k	0.18% $ 1.1m
Bruce Mast	Member of Board of Advisor	no data	Veri yok	Veri yok
David Muir	Member of Board of Advisor	no data	Veri yok	Veri yok
John Johnson	Independent Director	3.3yrs	US$215.00k	0.042% $ 262.8k
Kathy Weiler	Independent Director	less than a year	US$293.37k	Veri yok
Alan Levine	Independent Director	5.4yrs	US$217.50k	0.069% $ 431.6k
Amy Wendell	Independent Lead Director	8.1yrs	US$255.00k	0.18% $ 1.1m
William Burke	Independent Director	2.3yrs	US$220.00k	0.064% $ 399.3k
Joseph Tyndall	Independent Director	1.8yrs	US$205.00k	0.051% $ 322.8k

3.7yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AXGN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

Axogen Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chairman notifies of intention to sell stock

Chairman notifies of intention to sell stock

Axogen, Inc. Announces Chief Executive Officer Changes

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

Chairman exercised options and sold US$302k worth of stock

Vice President of Operations recently sold US$320k worth of stock

Recent updates

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Chairman notifies of intention to sell stock

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Chairman notifies of intention to sell stock

Price target increased by 8.8% to US$14.50

Axogen, Inc. Announces Chief Executive Officer Changes

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

AxoGen, Inc. Updates Earnings Guidance for the Full Year 2024

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

AxoGen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Forecast breakeven date pushed back to 2026

Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Forecast breakeven date moved forward to 2025

Axogen, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

New minor risk - Shareholder dilution

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Chairman exercised options and sold US$302k worth of stock

Consensus EPS estimates fall by 39%

Vice President of Operations recently sold US$320k worth of stock

AxoGen, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.10 loss in 3Q 2022)

Forecast breakeven date pushed back to 2026

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Insider recently sold US$94k worth of stock

AxoGen, Inc. Announces CFO Changes

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023

AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Price target decreased by 13% to US$14.20

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector

Independent Director recently bought US$66k worth of stock

Independent Director recently bought US$61k worth of stock

Axogen, Inc. Provides Revenue Guidance for the Year 2023

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

AxoGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Director recently sold US$366k worth of stock

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director recently sold US$69k worth of stock

AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Executive VP & CFO exercised options and sold US$58k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.5% to US$16.25

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

Executive VP & CFO exercised options and sold US$318k worth of stock

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

AxoGen, Inc. to Report Q4, 2022 Results on Mar 14, 2023

Forecast to breakeven in 2025

Chairman exercised options to buy US$282k worth of stock.

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director notifies of intention to sell stock